Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011, 305: 1873-1881. 10.1001/jama.2011.593.
Article
CAS
PubMed
Google Scholar
Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006, 6: 813-823.
Article
CAS
PubMed
Google Scholar
Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989, 81: 1088-1092. 10.1093/jnci/81.14.1088.
Article
CAS
PubMed
Google Scholar
Grever MR, Schepartz SA, Chabner BA: The National Cancer Institute: cancer drug discovery and development program. Semin Oncol. 1992, 19: 622-638.
CAS
PubMed
Google Scholar
Holbeck SL, Collins JM, Doroshow JH: Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther. 2010, 9: 1451-1460. 10.1158/1535-7163.MCT-10-0106.
Article
CAS
PubMed
PubMed Central
Google Scholar
Development Therapeutics Program NCI/NIH. http://www.dtp.nci.nih.gov/.
Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E: Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007, 67: 2226-2238. 10.1158/0008-5472.CAN-06-3633.
Article
CAS
PubMed
Google Scholar
Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, Huang F: Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol. 2007, 8: R255-10.1186/gb-2007-8-11-r255.
Article
PubMed
PubMed Central
Google Scholar
Gemma A, Li C, Sugiyama Y, Matsuda K, Seike Y, Kosaihira S, Minegishi Y, Noro R, Nara M, Seike M, Yoshimura A, Shionoya A, Kawakami A, Ogawa N, Uesaka H, Kudoh S: Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer. 2006, 6: 174-10.1186/1471-2407-6-174.
Article
PubMed
PubMed Central
Google Scholar
Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP: Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics. 2006, 7: 289-10.1186/1471-2164-7-289.
Article
PubMed
PubMed Central
Google Scholar
R language. http://www.r-project.org/.
Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 2010, 28: 4417-4424. 10.1200/JCO.2009.26.4325.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.
Article
CAS
PubMed
Google Scholar
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007, 13: 3207-3214. 10.1158/1078-0432.CCR-06-2765.
Article
CAS
PubMed
Google Scholar
Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68: 5405-5413. 10.1158/0008-5472.CAN-07-5206.
Article
CAS
PubMed
Google Scholar
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000, 24: 227-235. 10.1038/73432.
Article
CAS
PubMed
Google Scholar
Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR: Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 2003, 63: 8634-8647.
CAS
PubMed
Google Scholar
Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Kouros-Mehr H, Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN, Jay A: Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther. 2006, 5: 853-867. 10.1158/1535-7163.MCT-05-0155.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000, 2: 249-256. 10.1038/35010517.
Article
CAS
PubMed
Google Scholar
Goi T, Shipitsin M, Lu Z, Foster DA, Klinz SG, Feig LA: An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J. 2000, 19: 623-630. 10.1093/emboj/19.4.623.
Article
CAS
PubMed
PubMed Central
Google Scholar
Danen EH, van Rheenen J, Franken W, Huveneers S, Sonneveld P, Jalink K, Sonnenberg A: Integrins control motile strategy through a Rho-cofilin pathway. J Cell Biol. 2005, 169: 515-526. 10.1083/jcb.200412081.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005, 6: 56-68. 10.1038/nrm1549.
Article
CAS
PubMed
Google Scholar
Edwards DC, Sanders LC, Bokoch GM, Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999, 1: 253-259. 10.1038/12963.
Article
CAS
PubMed
Google Scholar
Sanders LC, Matsumura F, Bokoch GM, de Lanerolle P: Inhibition of myosin light chain kinase by p21-activated kinase. Science. 1999, 283: 2083-2085. 10.1126/science.283.5410.2083.
Article
CAS
PubMed
Google Scholar
Araujo J, Logothetis C: Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010, 36: 492-500. 10.1016/j.ctrv.2010.02.015.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA: The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res. 2007, 67: 9346-9355. 10.1158/0008-5472.CAN-06-4508.
Article
CAS
PubMed
Google Scholar
Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, Calipari N, Ottaviani D, Ibrahim T: Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets. 2010, 10: 46-54. 10.2174/156800910790980223.
Article
CAS
PubMed
Google Scholar
Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP: Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 2009, 283: 143-151. 10.1016/j.canlet.2009.03.035.
Article
CAS
PubMed
Google Scholar
Bulgaru AM, Mani S, Goel S, Perez-Soler R: Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther. 2003, 3: 269-279. 10.1586/14737140.3.3.269.
Article
CAS
PubMed
Google Scholar
Houghton PJ: Everolimus. Clin Cancer Res. 2010, 16: 1368-1372. 10.1158/1078-0432.CCR-09-1314.
Article
CAS
PubMed
PubMed Central
Google Scholar
Edick MJ, Tesfay L, Lamb LE, Knudsen BS, Miranti CK: Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death. Mol Biol Cell. 2007, 18: 2481-2490. 10.1091/mbc.E06-04-0261.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kline CL, Olson TL, Irby RB: Src activity alters alpha3 integrin expression in colon tumor cells. Clin Exp Metastasis. 2009, 26: 77-87. 10.1007/s10585-008-9215-x.
Article
CAS
PubMed
Google Scholar
Mitra SK, Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006, 18: 516-523. 10.1016/j.ceb.2006.08.011.
Article
CAS
PubMed
Google Scholar
Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF: FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 2004, 6: 154-161. 10.1038/ncb1094.
Article
CAS
PubMed
Google Scholar
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009, 458: 762-765. 10.1038/nature07823.
Article
CAS
PubMed
PubMed Central
Google Scholar
Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ: Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70: 8981-8987. 10.1158/0008-5472.CAN-10-1666.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kutty RK, Kutty G, Samuel W, Duncan T, Bridges CC, El-Sherbeeny A, Nagineni CN, Smith SB, Wiggert B: Molecular characterization and developmental expression of NORPEG, a novel gene induced by retinoic acid. J Biol Chem. 2001, 276: 2831-2840. 10.1074/jbc.M007421200.
Article
CAS
PubMed
Google Scholar
Sorrentino C, Di Carlo E: Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med. 2009, 180: 769-779. 10.1164/rccm.200903-0400OC.
Article
CAS
PubMed
Google Scholar
Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR: Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010, 70: 3780-3790. 10.1158/0008-5472.CAN-09-4439.
Article
CAS
PubMed
Google Scholar
Aksoy S, Brandriff BF, Ward A, Little PF, Weinshilboum RM: Human nicotinamide N-methyltransferase gene: molecular cloning, structural characterization and chromosomal localization. Genomics. 1995, 29: 555-561. 10.1006/geno.1995.9966.
Article
CAS
PubMed
Google Scholar
Xu J, Moatamed F, Caldwell JS, Walker JR, Kraiem Z, Taki K, Brent GA, Hershman JM: Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2003, 88: 4990-4996. 10.1210/jc.2002-021843.
Article
CAS
PubMed
Google Scholar
Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, Engel AM, Schneidinger B, Pfeffer M, Andres H, Karl J, Bodenmuller H, Ruschoff J, Henkel T, Rohr G, Rossol S, Rosch W, Langen H, Zolg W, Tacke M: Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res. 2005, 11: 6550-6557. 10.1158/1078-0432.CCR-05-0983.
Article
CAS
PubMed
Google Scholar
Tomida M, Mikami I, Takeuchi S, Nishimura H, Akiyama H: Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. J Cancer Res Clin Oncol. 2009, 135: 1223-1229. 10.1007/s00432-009-0563-y.
Article
CAS
PubMed
Google Scholar
Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D: Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 2008, 27: 6679-6689. 10.1038/onc.2008.264.
Article
CAS
PubMed
Google Scholar
Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK, Lin JY: Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 2011, 32: 138-145. 10.1093/carcin/bgq225.
Article
CAS
PubMed
Google Scholar
Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA. 2001, 98: 10787-10792. 10.1073/pnas.191368598.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006, 439: 353-357. 10.1038/nature04296.
Article
CAS
PubMed
Google Scholar
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10: 515-527. 10.1016/j.ccr.2006.10.008.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D: A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA. 2007, 104: 13086-13091. 10.1073/pnas.0610292104.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC, Yang PC: A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clin Cancer Res. 2009, 15: 7309-7315. 10.1158/1078-0432.CCR-09-1572.
Article
CAS
PubMed
Google Scholar
Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, Perez-Soler R: Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res. 2005, 11: 1572-1578. 10.1158/1078-0432.CCR-04-0993.
Article
CAS
PubMed
Google Scholar